Two genetic studies provided consistent evidence that the missense variants Ala316Thr and Arg131Gln in the glucagon-like peptide-1 receptor gene (GLP1R) are associated with lower fasting glucose and confer protection against CAD risk [49, 50]. The gene discussed is GLP1R; the disease is coronary artery disorder.